0.491
전일 마감가:
$0.4901
열려 있는:
$0.491
하루 거래량:
21,607
Relative Volume:
0.53
시가총액:
$10.07M
수익:
$2.82M
순이익/손실:
$-14.20M
주가수익비율:
-0.5776
EPS:
-0.85
순현금흐름:
$-15.13M
1주 성능:
-2.96%
1개월 성능:
+1.68%
6개월 성능:
-30.55%
1년 성능:
-51.86%
Talphera Inc Stock (TLPH) Company Profile
명칭
Talphera Inc
전화
650-216-3500
주소
1850 GATEWAY DRIVE, SAN MATEO
TLPH을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
TLPH
Talphera Inc
|
0.491 | 10.37M | 2.82M | -14.20M | -15.13M | -0.85 |
![]()
HLN
Haleon Plc Adr
|
11.35 | 50.14B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
ZTS
Zoetis Inc
|
168.63 | 72.38B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
RDHL
Redhill Biopharma Ltd Adr
|
1.79 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 45.51B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.78 | 19.45B | 16.54B | -1.64B | 749.00M | -1.45 |
Talphera Inc Stock (TLPH) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-01-28 | 개시 | Rodman & Renshaw | Buy |
2020-07-20 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
2019-11-11 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
2019-08-05 | 재개 | Credit Suisse | Outperform |
2019-07-10 | 재개 | Credit Suisse | Outperform |
2019-04-24 | 재개 | B. Riley FBR | Buy |
2019-02-15 | 개시 | Credit Suisse | Outperform |
2018-10-23 | 개시 | B. Riley FBR | Buy |
2017-10-13 | 다운그레이드 | Jefferies | Buy → Hold |
2017-10-13 | 재확인 | RBC Capital Mkts | Outperform |
2017-07-14 | 재개 | Jefferies | Buy |
2016-09-15 | 재확인 | ROTH Capital | Buy |
2016-08-05 | 다운그레이드 | Stifel | Buy → Hold |
2015-10-30 | 업그레이드 | Jefferies | Hold → Buy |
2015-10-05 | 재확인 | ROTH Capital | Buy |
2015-09-02 | 개시 | H.C. Wainwright | Buy |
2015-07-10 | 재개 | ROTH Capital | Buy |
2015-05-06 | 재확인 | Mizuho | Neutral |
2015-05-05 | 재확인 | RBC Capital Mkts | Outperform |
2015-03-10 | 재확인 | RBC Capital Mkts | Outperform |
2015-03-09 | 다운그레이드 | Mizuho | Buy → Neutral |
모두보기
Talphera Inc 주식(TLPH)의 최신 뉴스
Financial Review: Talphera (NASDAQ:TLPH) & Alterity Therapeutics (NASDAQ:ATHE) - Defense World
Talphera, Inc. (NASDAQ:TLPH) Q1 2025 Earnings Call Transcript - MSN
Talphera’s Strategic Advancements and Financial Stability Reinforce Buy Rating - TipRanks
Talphera outlines accelerated NEPHRO CRRT study timeline with completion targeted by end of 2025, supported by new site activations and $14.8M financing - MSN
Talphera, Inc. Earnings Call: Strategic Adjustments and Financial Progress - TipRanks
TLPH Prepares to Finalize NEPHRO CRRT Registration Trial | TLPH Stock News - GuruFocus
Talphera: Q1 Earnings Snapshot - Greenwich Time
Talphera Inc (TLPH) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions and FDA ... - Yahoo Finance
Talphera, Inc. Reports Q1 2025 Financial Results - TipRanks
Talphera Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Talphera Inc. outlines strategic shifts in Q1 2025 - Investing.com Nigeria
TLPH Reports Strong Q1 Revenue with Promising Study Progress | T - GuruFocus
Talphera Inc Reports Q1 2025 EPS Loss of $0.10, Beating Estimates; Revenue Details Unavailable - GuruFocus
TALPHERA, INC. SEC 10-Q Report - TradingView
TLPH Reports Strong Q1 Revenue with Promising Study Progress | TLPH Stock News - GuruFocus
Talphera Announces First Quarter 2025 Financial Results and Prov - GuruFocus
Talphera Cuts Net Loss 32%, Secures FDA Approval for Streamlined Clinical Trial Design - Stock Titan
Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update | TLPH Stock News - GuruFocus
Talphera reports Q1 EPS (10c), consensus (14c) - TipRanks
Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025 - Citizen Tribune
Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025 | TLPH Stock News - GuruFocus
All You Need to Know About Talphera (TLPH) Rating Upgrade to Strong Buy - Yahoo Finance
HC Wainwright Predicts Talphera’s Q1 Earnings (NASDAQ:TLPH) - Defense World
Talphera (TLPH) Upgraded to Buy: What Does It Mean for the Stock? - MSN
HC Wainwright Estimates Talphera FY2029 Earnings - Defense World
Talphera CEO Makes Bold Move with Major Stock Purchase! - TipRanks
Talphera CEO Vincent Angotti buys $124,999 in common stock By Investing.com - Investing.com Canada
Talphera CEO Vincent Angotti buys $124,999 in common stock - Investing.com
Talphera (NASDAQ:TLPH) Given Buy Rating at HC Wainwright - Defense World
Talphera, Inc. Earnings Call: Progress Amid Challenges - TipRanks
H.C. Wainwright maintains Buy on Talphera stock, $6 target By Investing.com - Investing.com Canada
Strategic Advancements and FDA Agreement Propel Talphera’s Positive Outlook with Buy Rating - TipRanks
H.C. Wainwright maintains Buy on Talphera stock, $6 target - Investing.com India
Talphera: Q4 Earnings Snapshot - CT Insider
Talphera Inc (TLPH) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial Insights - Yahoo Finance
Talphera Reports 2024 Financial Results and Study Update - TipRanks
Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad - MSN
Earnings call transcript: Talphera Inc Q4 2024 shows strategic focus - Investing.com India
FDA approves Talphera’s reduced NEPHRO CRRT study size By Investing.com - Investing.com South Africa
Earnings call transcript: Talphera Inc Q4 2024 shows strategic focus By Investing.com - Investing.com UK
TLPH stock touches 52-week low at $0.5 amid market challenges By Investing.com - Investing.com South Africa
TALPHERA, INC. SEC 10-K Report - TradingView
Talphera Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Talphera Inc (TLPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Talphera Inc 주식 (TLPH) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Aslam Shakil | Chief Medical Officer |
Jun 14 '24 |
Buy |
1.07 |
5,000 |
5,357 |
37,695 |
Aslam Shakil | Chief Medical Officer |
Jun 13 '24 |
Buy |
0.98 |
695 |
681 |
32,695 |
Angotti Vincent J. | CHIEF EXECUTIVE OFFICER |
Dec 05 '24 |
Buy |
0.64 |
5,000 |
3,200 |
208,066 |
ASADORIAN RAFFI | Chief Financial Officer |
Dec 02 '24 |
Sale |
0.77 |
155 |
119 |
37,578 |
Angotti Vincent J. | CHIEF EXECUTIVE OFFICER |
Nov 27 '24 |
Buy |
0.73 |
5,000 |
3,650 |
203,066 |
자본화:
|
볼륨(24시간):